BOLD Financials | Key Metrics & Investor Analysis

The financial statements for BOLD (BOLD) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.

See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.

Financial Statements

Related peers

Compare More →
ANTX
AN2 Therapeutics, Inc.
$3.26
+9.40%
NXTC
NextCure, Inc.
$12.59
-1.41%
INTS
Intensity Therapeutics, Inc.
$5.30
-1.12%
D
Dominion Energy, Inc.
$62.38
-2.09%
QTTB
Q32 Bio Inc.
$6.09
+3.57%
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%

Frequently Asked Questions

What are BOLD's latest financial results?

Review BOLD's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.

How has BOLD's revenue and net income changed over time?

Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.

What is BOLD's cash flow situation and liquidity?

Cash flow statements reveal how BOLD generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.

How does BOLD's financial performance compare to industry peers?

Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether BOLD is outperforming or lagging within its sector.

Are BOLD's financial statements showing sustainable profitability?

By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether BOLD's profits are repeatable and supported by strong fundamentals.